Literature DB >> 22936733

Treating myeloma: the future is already here!

Ola Landgren1, Neha Korde.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22936733     DOI： 10.1182/blood-2012-06-434571

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.

Authors:  Aaron Flanders; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Blood       Date:  2013-08-08       Impact factor: 22.113

2.  Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.

Authors:  Peter M Voorhees; Jacob Laubach; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

3.  Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors:  S Y Kristinsson; W F Anderson; O Landgren
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

4.  Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.

Authors:  Benjamin M Cherry; Neha Korde; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Marcia Mulquin; Diamond Zuchlinski; Mary Ann Yancey; Irina Maric; Katherine R Calvo; Raul Braylan; Maryalice Stetler-Stevenson; Constance Yuan; Prashant Tembhare; Adriana Zingone; Rene Costello; Mark J Roschewski; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2013-07-29

5.  Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.

Authors:  Nassera Aouali; Angeliki Broukou; Manon Bosseler; Olivier Keunen; Vincent Schlesser; Bassam Janji; Valerie Palissot; Philippe Stordeur; Guy Berchem
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.